Comparing mosquito® LäuseShampoo with Infectopedicul® lotion
| ISRCTN | ISRCTN48669688 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN48669688 |
| EudraCT/CTIS number | 2010-019804-21 |
| Secondary identifying numbers | CTWE01 |
- Submission date
- 23/03/2010
- Registration date
- 08/04/2010
- Last edited
- 05/02/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Some head louse treatments are not effective because they are difficult to use or are affected by insecticide resistance. This trial looked at a shampoo containing soya oil as an active material to coat the lice (mosquito®LäuseShampoo) and compared it with an insecticide-based product containing 0.5% permethrin used extensively in Germany (InfectoPedicul® lotion).
Who can participate?
Anyone over 2 years of age who had head lice could take part.
What does the study involve?
The participants were randomly allocated to receive one of the two treatment methods: shampoo or lotion. Both treatments were applied on the first day, with repeat treatment after 9 days, and there were four follow-ups over 2 weeks to see how well they worked.
What are the possible benefits and risks of participating?
The possible benefit of the trial was that patients could get rid of their head lice without charge. The possible risks of the trial were discomfort or irritation where the treatment was applied either during or after the treatment.
Where is the study run from?
Medical Entomology Centre, Insect Research & Development Limited, UK.
When is the study starting and how long is it expected to run for?
The study started in June 2010 and ran until December 2010.
Who is funding the study?
Wepa Apothekenbedarf GmbH & Co KG.
Who is the main contact?
Mr Ian Burgess
ian@insectresearch.com
Contact information
Scientific
Medical Entomology Centre
Insect Research & Development Limited
6 Quy Court
Colliers Lane
Stow-cum-Quy
Cambridge
CB25 9AU
United Kingdom
| Phone | +44 (0)1223 810070 |
|---|---|
| ian@insectresearch.com |
Study information
| Study design | Randomised controlled assessor blind parallel group study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Other |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information booklet |
| Scientific title | A randomised, controlled, assessor-blind, clinical investigation of the activity of mosquito® LäuseShampoo compared with Infectopedicul® permethrin 0.5% lotion in the treatment of head lice |
| Study objectives | To investigate: 1. Non-inferiority of mosquito® LäuseShampoo to Infectopedicul® in the eradication of head louse infestation 2. If a sufficient difference in efficacy is identified to detect superiority of mosquito® LäuseShampoo compared with Infectopedicul® 3. To compare the products for safety, ease of application and participant acceptability |
| Ethics approval(s) | Added 05/02/2014: Oxfordshire REC Committee A, ref: 10/H0604/30 |
| Health condition(s) or problem(s) studied | Head louse infestation |
| Intervention | Participants will be randomly divided into two equal groups. Half the participants (48) will receive mosquito® LäuseShampoo (modified coconut oil and soya oil based shampoo): the product is first used like an ordinary shampoo and partially towel dried. The product will be applied directly to the damp hair. Sufficient product will be applied to the hair and scalp that when thoroughly massaged in produces a homogenous and stable foam, which covers all the hair and the scalp. If no such foam is built, more product has to be applied. The foamed product will be left in place for 30 minutes (a shower cap will be used to secure the foam) before being rinsed off with warm water and towel dried. The product is then reapplied to produce a stable foam and left in place for a further 30 minutes (maximum dose 100 ml per treatment application). The product will be reapplied at Day 9. The other half (48) will receive Infectopedicul® 0.5% permethrin alcoholic lotion: The product will be applied directly to washed and towel dried hair. Sufficient product will be applied to saturate the hair and scalp (maximum dose 100 ml per application). The product will be left in place for 30 minutes before being rinsed off with warm water. The product will be reapplied at Day 9. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase IV |
| Drug / device / biological / vaccine name(s) | mosquito® LäuseShampoo, Infectopedicul® lotion |
| Primary outcome measure | To investigate the non-inferiority of mosquito® LäuseShampoo in comparison with Infectopedicul® lotion in the eradication of head louse infestation, defined as no evidence of head lice, assessed between completion of the second application of treatment on day 9 and day 14 (the first treatment being applied on day 0). |
| Secondary outcome measures | 1. If there is sufficient margin in efficacy, to detect superiority of efficacy of mosquito® LäuseShampoo over Infectopedicul® lotion in the eradication of head louse infestation 2. To compare mosquito® LäuseShampoo with Infectopedicul® lotion with regard to the following factors: 2.1. Safety of the products monitored by observation for adverse events on days 0, 2, 9, 11, and 14 of the study 2.2. Ease of use by investigators, assessed by a questionnaire on the day of the first treatment 2.3. Participant acceptability, assessed by a questionnaire at the assessment on day 2 |
| Overall study start date | 01/05/2010 |
| Completion date | 31/08/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Other |
| Sex | Both |
| Target number of participants | 96 |
| Key inclusion criteria | 1. Both males and females aged 2 years and over with no upper age limit 2. Participants who upon examination, are confirmed to have at least five live head lice 3. Participants who give written informed consent, or if the participant is below 16 years of age whose parent/guardian gives written informed consent to participate in the study 4. Participants who will be available for home visits by study team members over the 14 days following first treatment |
| Key exclusion criteria | 1. People younger than 2 years 2. People with a known sensitivity to pyrethroid insecticides like permethrin, chrysanthemums, nuts, soya, or any of the ingredients in mosquito® LäuseShampoo or Infectopedicul® lotion 3. People with asthma or a similar respiratory condition 4. People with a secondary bacterial infection of the scalp (e.g. impetigo) or who have a long term scalp condition (e.g. psoriasis of the scalp) 5. People who have been treated with other head lice products within the previous two weeks 6. People who have been treated with the antibiotics co-trimoxazole, trimethoprim or any other medical treatment which could interfere with the study treatment within the previous four weeks, or who are currently taking such a course 7. People who have bleached, permanently coloured, or permanent waved their hair within the previous four weeks 8. People or parents/guardians not giving written consent or withdrawal of the written consent 9. Pregnant or nursing mothers. Any potential participant in menses should confirm that they are not or not likely to be pregnant or are taking an appropriate form of contraception. In case of doubt a urine pregnancy test may be performed prior to entry. 10. People who have participated in another clinical study within 1 month before entry to this study 11. People who have already participated in this clinical study |
| Date of first enrolment | 01/05/2010 |
| Date of final enrolment | 31/08/2010 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
CB25 9AU
United Kingdom
Sponsor information
Industry
Am Fichtenstrauch 6-10
Hillscheid
56204
Germany
| Website | http://www.wepa-apothekenbedarf.de/wepa/Startseite/ |
|---|---|
"ROR" |
https://ror.org/01y84kk86 |
Funders
Funder type
Government
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/04/2011 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No |
